Toggle navigation
HOME
NEWSFEEDS
Healthcare Industry News
Medical Devices
Biopharmaceuticals
Diagnostics
Cardiology
Interventional
Neuro
Oncology
Orthopaedic
Surgery
People
Distribution
FDA Actions
Regulatory (INTL)
Mergers & Acquisitions
Venture Capital
INDEPENDENT REPS
For MANUFACTURERS:
Find Reps NOW
Post Your Rep Opportunity
Not sure? Let us help!
For REPS and DISTRIBUTORS:
Not in FindReps? Contact us!
ISR REGISTRY:
Independent Sales Reps - USA
Not a MEMBER Yet?
Join HSMN
FORUMS
Independent Sales Reps & Distributors
The Network Bulletin Board
Getting Started in Medical Sales
Show All Forums
RESOURCES
FindReps®
Help / FAQs
INDUSTRY LINKS:
Medical Device Companies
Biopharmaceutical Companies
Professional Organizations
Government & Regulatory
Products & Services
Venture Capital
MEMBERS
Join HSMN
Forgot Username / Password
Help / FAQs
PASSWORD REQUIRED:
Company Links Listing (Manufacturers)
Products & Services Listing (Vendors)
Post in Forums
Renew Membership
Change Password
Update Contact Info
Something else? - Contact Us
ABOUT
About HSMN
Membership Info
FindReps®
Join HSMN
Help / FAQs
Submit News Release
Info for Advertisers
Contact Us
Searching News Database:
solanezumab
HSMN NewsFeed - 21 Jul 2020
Data from Lilly at Alzheimer's Association International Conference 2020(R) (AAIC 2020) to Showcase Clinical Advances in Alzheimer's Research
Biopharmaceuticals
Neurology
HSMN NewsFeed - 10 Feb 2020
Lilly Announces Topline Results for Solanezumab from the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Study
Biopharmaceuticals
Neurology
HSMN NewsFeed - 9 Dec 2016
Lilly Announces Detailed Results of Solanezumab Phase 3 EXPEDITION3 Study at the Clinical Trials on Alzheimer's Disease (CTAD) 2016 Meeting
Biopharmaceuticals
Neurology
HSMN NewsFeed - 23 Nov 2016
Neurotrope Issues Statement On Eli Lilly's Solanezumab
Biopharmaceuticals
Neurology
HSMN NewsFeed - 23 Nov 2016
Lilly Announces Top-Line Results of Solanezumab Phase 3 Clinical Trial
Biopharmaceuticals
Neurology
HSMN NewsFeed - 15 Mar 2016
Lilly Announces Change to Primary Endpoint of EXPEDITION3 Study
Biopharmaceuticals
Neurology
HSMN NewsFeed - 3 Sep 2014
Voyager Therapeutics Appoints Steven Paul, M.D., to Chief Executive Officer
Biopharmaceuticals
Neurology
Personnel
HSMN NewsFeed - 12 Dec 2012
Lilly Provides Update on Next Steps for Solanezumab
Biopharmaceuticals
Neurology
HSMN NewsFeed - 24 Aug 2012
Eli Lilly and Company Announces Top-Line Results on Solanezumab Phase 3 Clinical Trials in Patients with Alzheimer's Disease
Biopharmaceuticals
Neurology
HSMN NewsFeed - 17 Aug 2010
Lilly Halts Development of Semagacestat for Alzheimer's Disease Based on Preliminary Results of Phase III Clinical Trials
Biopharmaceuticals
Neurology
HSMN NewsFeed - 13 Nov 2009
Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor
Biopharmaceuticals
Personnel
Return to NewsFeed
